Nuvation Bio Inc [NYSE: NUVB] closed the trading session at $3.27 on 2025-09-16. The day’s price range saw the stock hit a low of $3.09, while the highest price level was $3.41.
The stocks have a year to date performance of 6.86 percent and weekly performance of -2.39 percent. The stock has been moved at 56.46 percent over the last six months. The stock has performed 18.91 percent around the most recent 30 days and changed 75.81 percent over the most recent 3-months.
If compared to the average trading volume of 6.22M shares, NUVB reached to a volume of 6324149 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Nuvation Bio Inc [NUVB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NUVB shares is $8.14 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NUVB stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citizens JMP have made an estimate for Nuvation Bio Inc shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on April 23, 2025. While these analysts kept the previous recommendation, Jefferies raised their target price from $1.40 to $10. The new note on the price target was released on March 27, 2024, representing the official price target for Nuvation Bio Inc stock. Previously, the target price had yet another raise to $5, while BTIG Research analysts kept a Buy rating on NUVB stock. On January 06, 2023, analysts decreased their price target for NUVB shares from 5 to 2.
The Price to Book ratio for the last quarter was 2.96, with the Price to Cash per share for the same quarter was set at 1.77.
NUVB stock trade performance evaluation
Nuvation Bio Inc [NUVB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.39. With this latest performance, NUVB shares gained by 18.91% in over the last four-week period, additionally plugging by 56.46% over the last 6 months – not to mention a rise of 22.93% in the past year of trading.
Nuvation Bio Inc [NUVB]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Nuvation Bio Inc [NUVB] shares currently have an operating margin of -1564.86% and a Gross Margin at 20.25%. Nuvation Bio Inc’s Net Margin is presently recorded at -1413.43%.
Nuvation Bio Inc (NUVB) Capital Structure & Debt Analysis
According to recent financial data for Nuvation Bio Inc. ( NUVB), the Return on Equity (ROE) stands at -64.40%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -32.67%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Nuvation Bio Inc’s Return on Invested Capital (ROIC) is -35.84%, showcasing its effectiveness in deploying capital for earnings.
Nuvation Bio Inc (NUVB) Efficiency & Liquidity Metrics
Based on Nuvation Bio Inc’s (NUVB) latest financial statements, the Debt-to-Equity Ratio is 0.55%, indicating its reliance on debt financing relative to shareholder equity.
Nuvation Bio Inc (NUVB) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Nuvation Bio Inc. (NUVB) effectively leverages its workforce, generating an average of -$922272.73 per employee. The company’s liquidity position is robust, with a Current Ratio of 9.39% and a Quick Ratio of 9.38%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Nuvation Bio Inc [NUVB] stock
With the latest financial reports released by the company, Nuvation Bio Inc posted -0.12/share EPS, while the average EPS was predicted by analysts to be reported at -0.1/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NUVB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Nuvation Bio Inc go to 40.81%.
Nuvation Bio Inc [NUVB]: Institutional Ownership
There are presently around $66.74%, or 82.42%% of NUVB stock, in the hands of institutional investors. The top three institutional holders of NUVB stocks are: FMR LLC with ownership of 28.82 million shares, which is approximately 11.7767%. ECOR1 CAPITAL, LLC, holding 19.21 million shares of the stock with an approximate value of $$56.09 million in NUVB stocks shares; and ECOR1 CAPITAL, LLC, currently with $$47.41 million in NUVB stock with ownership which is approximately 6.6343%.
